eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
SCImago Journal & Country Rank

1/2019
vol. 11
 
Share:
Share:
more
 
 
abstract:
Original paper

Long-term results of chemoradiation plus pulsed-dose-rate brachytherapy boost in anal canal carcinoma: A mono-institutional retrospective analysis

Alessandra Arcelli, Milly Buwenge, Gabriella Macchia, Silvia Cammelli, Francesco Deodato, Savino Cilla, Andrea Galuppi, Valeria Panni, Gian Carlo Mattiucci, Luca Tagliaferri, Alessio G. Morganti

J Contemp Brachytherapy 2019; 11, 1: 21–27
Online publish date: 2019/02/28
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Purpose
Concurrent chemoradiation (CCRT) is the standard curative treatment of anal canal cancer (ACC). The role of a brachytherapy (BRT) boost in this setting is still debated. Therefore, the aim of this analysis was to retrospectively evaluate the clinical outcomes in a large cohort of ACC patients treated with CCRT plus BRT boost or external beam radiotherapy (EBRT) boost.

Material and methods
Patients with non-metastatic ACC, treated in our department between January 2003 and December 2014 were included in this analysis. The initial treatment was based on EBRT to the pelvis (prescribed dose, 45 Gy/1.8 Gy) plus concurrent chemotherapy (5-fluorouracil and mitomycin-C). Patients received a pulsed-dose-rate BRT boost on the primary tumor (median dose, 20 Gy; range, 13-25 Gy) 2-3 weeks after the end of CCRT. In patients with contraindications to BRT, an EBRT boost (prescribed dose, 16 Gy, 2 Gy/fraction) was delivered immediately after CCRT.

Results
One-hundred-twenty-three patients were included in this analysis (median age, 61 years; range, 36-93 years; squamous-cell carcinoma, 78%; HIV+, 6%; median follow-up, 71 months; range, 2-158 months). The actuarial 5-year local control (LC), distant metastasis-free survival, colostomy-free survival, and overall survival (OS) rates were 81.7%, 92.3%, 62.3%, and 74.0%, respectively. At univariate analysis, patients aged ≤ 65 years (p < 0.010), cT1-2 stage (p = 0.004), and receiving a BRT boost (p = 0.015) showed significantly improved OS. At multivariate analysis, advanced tumor stage cT3-cT4 (HR, 2.12; 95% CI: 1.09-4.14; p = 0.027), and age > 65 years (HR, 3.03; 95% CI: 1.54-5.95; p = 0.001) significantly predicted increased risk of mortality. The crude rate of toxicity-related colostomies was 4.9%.

Conclusions
The role of BRT boost in ACC remains unclear since the outcomes were not clearly different compared to CCRT alone. However, further improvement of clinical results in ACC treatment is needed, and therefore prospective trials based on advanced (image-guided/adapted) BRT techniques are warranted.

keywords:

anal carcinoma, brachytherapy, colostomy-free survival

references:
National Cancer Institute. SEER cancer statistics factsheets: anal cancer. http://seer.cancer.gov/statfacts/html/anus.html. Accessed September 24, 2014.
https://seer.cancer.gov/statfacts/html/anus.html. Accessed July 29, 2018.
Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-236.
Rousseau DL, Thomas CR, Petrelli NJ, Kahlenberg MS. Squamous cell carcinoma of the anal canal. Surg Oncol 2005; 14: 121-132.
Epidermoid anal cancer: Results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 1996; 348: 1049-1054.
Bartelink H, Roelofsen F, Eschwege F et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997; 15: 2040-2049.
Flam M, John M, Pajak TF et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: Results of a phase III randomized intergroup study. J Clin Oncol 1996; 14: 2527-2539.
Ajani JA, Winter KA, Gunderson LL et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: A randomized controlled trial. JAMA 2008; 299: 1914-1921.
Gunderson LL, Winter KA, Ajani JA et al. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol 2012; 30: 4344-4351.
Frakulli R, Buwenge M, Cammelli S et al. Brachytherapy boost after chemoradiation in anal cancer: a systematic review. J Contemp Brachytherapy 2018; 10: 246-253.
Amin MB, Edge S, Greene F et al. (Eds.). AJCC Cancer Staging Manual (8th edition). Springer International Publishing: American Joint Commission on Cancer. 2017.
International Commission on Radiation Units and Measurements ICRU Report 62. Prescribing, recording, and reporting photon beam therapy (Supplement to ICRU Report 50), ICRU, Bethesda, MD (1999).
Dutreix A, Marinello G. The Paris system. In: Pierquin B, Wilson JF, Chassagne D, eds. Modern brachytherapy. New York: Masson, 1987: 25-42
Kaplan E, Meier P. Nonparametric estimation from incomplete observations. Am J Stat Assoc 1958; 53: 457-481.
Peto R, Peto J. Asymptotically efficient rank invariant procedures. J R Stat Soc 1972; 135: 185-207.
Cox DR. Regression models and life tables (with discussion). Journal of the Royal Statistical Society, Series B 1972; 74: 187-220.
Franco P, Arcadipane F, Ragona R et al. Locally advanced (T3-T4 or N+) anal cancer treated with simultaneous integrated boost radiotherapy and concurrent chemotherapy. Anticancer Res 2016; 36: 2027-2032.
Franco P, Arcadipane F, Ragona R et al. Early-stage node-negative (T1-T2N0) anal cancer treated with simultaneous integrated boost radiotherapy and concurrent chemotherapy. Anticancer Res 2016; 36: 1943-1948.
Janssen S, Glanzmann C, Bauerfeind P et al. Clinical experience of SIB-IMRT in anal cancer and selective literature review. Radiat Oncol 2014; 9: 199.
Tomasoa NB, Meulendijks D, Nijkamp J et al. Clinical outcome in patients treated with simultaneous integrated boost-intensity modulated radiation therapy (SIB-IMRT) with and without concurrent chemotherapy for squamous cell carcinoma of the anal canal. Acta Oncol 2016; 55: 760-766.
Zimmermann M, Beer J, Bodis S et al. PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer. Acta Oncol 2017; 56: 1734-1740.
Tagliaferri L, Manfrida S, Barbaro B et al. MITHRA – multiparametric MR/CT image-adapted brachytherapy (MR/CT-IABT) in anal canal cancer: a feasibility study. J Contemp Brachytherapy 2015; 7: 336-345.
Kapoor R, Khosla D, Shukla AK et al. Dosimetric and clinical outcome in image-based high-dose-rate interstitial brachytherapy for anal cancer. Brachytherapy 2014; 13: 388-393.
 
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe